ORIGINAL ARTICLE   

Chirurgia 2023 August;36(4):173-7

DOI: 10.23736/S0394-9508.22.05467-5

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Incidence of beta-lactamases producing Enterobacteriaceae-associated intra-abdominal surgical site infection

Mahmoud AL-AWAYSHEH ✉

Mutah University, Al Karak, Jordan

BACKGROUND: Once extended-spectrum beta-lactamases (ESBLs) producing Enterobacteriaceae have been globally emerged, prevalence of cefazoline failure cases in surgical site infections have been exponentially increased. Our objectives in this study were to investigate the incidence rate of ESBLs producing Enterobacteriaceae associated intra-abdominal infections (IAIs) in Jordanian cohort.
METHODS: A retrospective study was conducted over 1 year. All ESBLs producing Enterobacteriaceae associated IAIs isolates were collected from either the IA surgical site related IAIs via needle aspirates or surgical samples. Independent T, Mann-Whitney U, and χ² tests were used to analyze our tested variables across ESBLs producing Enterobacteriaceae associated IAIs (Cohort I) and non-ESBLs producing Enterobacteriaceae-associated IAIs (Cohort II).
RESULTS: The median age of the studied cohort was 58 years (IQR 49-67 years) and majority of patients were male (57.97%). Overall Enterobacteriaceae associated IAIs were 61.61%, distributed to 46.38% in Cohort I and 53.62% in Cohort II. The 1-year propensity was increased by 22.3% (95% CI 13%-28%, P<0.05, x² for trend). 1-year overall mortality rate was reported at 36.23%.
CONCLUSIONS: Preemptively ordering of carbapenems or Ceftolozane/Tazobactam should be considered in certain intrabdominal surgery scenarios, especially for individuals originating from a country with a high prevalence rate.

KEY WORDS: Beta-lactamases; Enterobacteriaceae; Intraabdominal infections; Carbapenems